Cargando…
Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
BACKGROUND: Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be translated into clinical practice because of its hematopoiesis-associated side effects while non-erythropoietic asialo-rhuEPO is...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327940/ https://www.ncbi.nlm.nih.gov/pubmed/30671548 http://dx.doi.org/10.1016/j.bbrep.2019.01.004 |
_version_ | 1783386572795674624 |
---|---|
author | Kittur, Farooqahmed S. Lin, Yuan Arthur, Elena Hung, Chiu-Yueh Li, P. Andy Sane, David C. Xie, Jiahua |
author_facet | Kittur, Farooqahmed S. Lin, Yuan Arthur, Elena Hung, Chiu-Yueh Li, P. Andy Sane, David C. Xie, Jiahua |
author_sort | Kittur, Farooqahmed S. |
collection | PubMed |
description | BACKGROUND: Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be translated into clinical practice because of its hematopoiesis-associated side effects while non-erythropoietic asialo-rhuEPO is unavailable in large quantities for clinical studies. This study was designed to investigate the cardiomyocyte protective potential of plant-produced asialo-rhuEPO (asialo-rhuEPO(P)) against staurosporine (STS)-induced injury in HL-1 murine cardiomyocytes and identify cellular pathway(s) responsible for its cardioprotection. METHODS: HL-1 cardiomyocytes were simultaneously treated with STS and asialo-rhuEPO(P). Cellular injury, apoptosis, and cell viabilities were measured by LDH assay, Hoechst staining and trypan blue exclusion method, respectively while western blotting was used to study its effects on apoptosis and autophagy hallmarks. RESULTS: Our results showed that 20 IU/ml asialo-rhuEPO(P) provided 39% protection to cardiomyocytes compared to STS-treated cells, which is 2-fold better than that of mammalian cell-produce rhuEPO (rhuEPO(M)). Asialo-rhuEPO(P) was found to suppress activation of proapoptotic kinase Mst1 (mammalian Sterile-20-like kinase 1) and FOXO3, leading to inhibition of apoptotic pathway and restoration of autophagy as indicated by the reduction of fragmented/condensed nuclei, altered ratios of Bax/Bcl2, p-Bad/Bad, cytosol/mitochondrial cyt c and caspase-3 activation, and the restored levels of autophagy markers Beclin1, p62 and LC3B-II. Additionally, Akt was found to be activated and FOXO3 was phosphorylated on Ser253, suggesting inhibition of FOXO3 transcriptional function. CONCLUSIONS: Asialo-rhuEPO(P)-mediated cardioprotection occurs through activation of PI3K/Akt pathway leading to suppression of Mst1 activation and promoting cardiomyocyte survival. GENERAL SIGNIFICANCE: Asialo-rhuEPO(P) could be used to modulate Mst1 activity elevated under numerous pathological states. |
format | Online Article Text |
id | pubmed-6327940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63279402019-01-22 Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation Kittur, Farooqahmed S. Lin, Yuan Arthur, Elena Hung, Chiu-Yueh Li, P. Andy Sane, David C. Xie, Jiahua Biochem Biophys Rep Review Article BACKGROUND: Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be translated into clinical practice because of its hematopoiesis-associated side effects while non-erythropoietic asialo-rhuEPO is unavailable in large quantities for clinical studies. This study was designed to investigate the cardiomyocyte protective potential of plant-produced asialo-rhuEPO (asialo-rhuEPO(P)) against staurosporine (STS)-induced injury in HL-1 murine cardiomyocytes and identify cellular pathway(s) responsible for its cardioprotection. METHODS: HL-1 cardiomyocytes were simultaneously treated with STS and asialo-rhuEPO(P). Cellular injury, apoptosis, and cell viabilities were measured by LDH assay, Hoechst staining and trypan blue exclusion method, respectively while western blotting was used to study its effects on apoptosis and autophagy hallmarks. RESULTS: Our results showed that 20 IU/ml asialo-rhuEPO(P) provided 39% protection to cardiomyocytes compared to STS-treated cells, which is 2-fold better than that of mammalian cell-produce rhuEPO (rhuEPO(M)). Asialo-rhuEPO(P) was found to suppress activation of proapoptotic kinase Mst1 (mammalian Sterile-20-like kinase 1) and FOXO3, leading to inhibition of apoptotic pathway and restoration of autophagy as indicated by the reduction of fragmented/condensed nuclei, altered ratios of Bax/Bcl2, p-Bad/Bad, cytosol/mitochondrial cyt c and caspase-3 activation, and the restored levels of autophagy markers Beclin1, p62 and LC3B-II. Additionally, Akt was found to be activated and FOXO3 was phosphorylated on Ser253, suggesting inhibition of FOXO3 transcriptional function. CONCLUSIONS: Asialo-rhuEPO(P)-mediated cardioprotection occurs through activation of PI3K/Akt pathway leading to suppression of Mst1 activation and promoting cardiomyocyte survival. GENERAL SIGNIFICANCE: Asialo-rhuEPO(P) could be used to modulate Mst1 activity elevated under numerous pathological states. Elsevier 2019-01-09 /pmc/articles/PMC6327940/ /pubmed/30671548 http://dx.doi.org/10.1016/j.bbrep.2019.01.004 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Kittur, Farooqahmed S. Lin, Yuan Arthur, Elena Hung, Chiu-Yueh Li, P. Andy Sane, David C. Xie, Jiahua Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation |
title | Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation |
title_full | Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation |
title_fullStr | Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation |
title_full_unstemmed | Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation |
title_short | Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation |
title_sort | recombinant asialoerythropoetin protects hl-1 cardiomyocytes from injury via suppression of mst1 activation |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327940/ https://www.ncbi.nlm.nih.gov/pubmed/30671548 http://dx.doi.org/10.1016/j.bbrep.2019.01.004 |
work_keys_str_mv | AT kitturfarooqahmeds recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation AT linyuan recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation AT arthurelena recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation AT hungchiuyueh recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation AT lipandy recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation AT sanedavidc recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation AT xiejiahua recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation |